Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

SHARMA, PADMANEE

One or more keywords matched the following items that are connected to SHARMA, PADMANEE

Item Type	Name
Academic Article	CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.
Academic Article	Novel cancer immunotherapy agents with survival benefit: recent successes and next steps.
Academic Article	Prostate cancer: combination of vaccine plus ipilimumab--safety and toxicity.
Academic Article	Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.
Academic Article	Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy.
Academic Article	CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy.
Academic Article	The future of immune checkpoint therapy.
Academic Article	A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling
Academic Article	Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody
Academic Article	Review of immune-related adverse events in prostate cancer patients treated with ipilimumab
Academic Article	Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
Academic Article	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032)
Academic Article	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.
Academic Article	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
Academic Article	A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling.
Academic Article	Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody.
Academic Article	Loss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.
Academic Article	Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
Academic Article	Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies.
Academic Article	VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.
Academic Article	Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.
Academic Article	Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
Academic Article	Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies.
Academic Article	Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade.
Academic Article	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Academic Article	Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy.
Academic Article	Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers.
Academic Article	CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Academic Article	Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.
Academic Article	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
Concept	Ipilimumab
Academic Article	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.
Academic Article	Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses.
Academic Article	Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy.
Academic Article	Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer.
Academic Article	Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial.
Academic Article	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Academic Article	Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ? Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.
Academic Article	Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Academic Article	Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.
Academic Article	Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.
Academic Article	Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
Academic Article	Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032).

Search Criteria

Ipilimumab